Help Your Patients

Take Control

Reliefband Technologies leads the way in wearable anti-emesis technology

Rx Only

Designed To Put Patients In Control of Their Treatment

CINV

Without Drugs, Without Delay

For the treatment of chemotherapy-induced nausea and vomiting.

Learn More

Personal Control

Delivers Patient Satisfaction

Patient can adjust intensity to match their symptoms.

Learn More

Post-Operative Nausea

Without Drugs, Without Delay

For the management of Post-Operative Nausea as an adjunct to anti-emetics

Learn More

Counting The Costs Of CINV

Nausea & Vomiting may result in prolonged hospitalizations, an inability to continue usual activities, depression, the need for additional support, and a greater impact on health care costs. A review of 12 published studies1 found that the direct cost of care was higher for patients who did not receive adequate prophylaxis for CINV. Indirect costs related to lost work hours were also higher for patients with uncontrolled CINV. Another study examined 178 patients receiving highly or moderately emetogenic chemotherapy for their first chemotherapy course.Higher direct and indirect health care costs and lower Functional Living Index—Emesis (FLIE) scores for quality of life were seen in patients who failed CINV prophylaxis. A study of 19,139 patients in the Premier Perspective database who received prophylaxis to, all of. In those with uncontrolled CINV, the overall mean additional costs were $5,299 per episode.3

Mode Of Action

Reliefband Technologies’ advanced, wearable neuromodulation devices generate sophisticated programmed transdermal pulses with a highly-specific waveform, frequency, and amplitude to stimulate the median nerve on the underside of the wrist.

These precise transdermal pulses generate signals within the median nerve that travel via the peripheralnervous system to the central nervous system’s higher emetic control center in the brainstem. These signals positively modulate various natural neural pathways involved in regulating emesis via the vagus nerve to restore normal gastric rhythms.

A proprietary pulse is generated from the underside of the device that stimulates the median nerve.

The generated signals travel to the body’s central nervous system and the higher emetic center of the brain.4

The signals modulate the neural pathways between the brain and the stomach, via the vagus nerve, restoring normal gastric rhythm and relieving nausea.5,6

Direction For Use

1 Area

dir-1

Find the starting area on the wrist. Using either wrist, the correct area is in between the two tendons on the underside of the wrist – two finger widths from the first (proximal) crease at the wrist.

2 Apply

dir-2

Clean the area first. Apply a small drop of gel and spread in a circle about the size of a large coin with an even sheen

3 Adjust & Activate

Place the device over the gelled area and fasten device snugly. Press the power button to turn on the device. Starting at power level 1, increase stimulation until tingling is felt in palm and middle finger at a comfortable level. Press the power button for 3 seconds to turn off.

Highly Effective,
Clinically Proven

Rapid Onset Of Action

The onset of action and symptom relief begins within minutes of activation – can be used preventively or even after symptoms appear.

Drug Free

Free from the unwanted side effects or potential drug ? drug interactions associated with antiemetic drugs

Patient?Controlled Therapy

Patients can easily activate and adjust the level of stimulation, depending on the intensity of their symptoms.

References

  1. Carlotto A, Hogsett VL, Maiorini EM, et al.: The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics 31 (9): 753-66, 2013.
  2. Haiderali A, Menditto L, Good M, et al.: Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19 (6): 843-51, 2011.
  3. Burke TA, Wisniewski T, Ernst FR: Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19 (1): 131-40, 2011.
  4. Yoo SS, Teh EK, Blinder RA, et al. NeuroImage. 2004; 22: 932-940.
  5. Koch KM. Dig Dis & Sci. 1990;44(8):53S-7S.
  6. Hu S, Stern RM, Koch KL, et al. Gastroenterology. 1992; 102(8):1855-58.